Diametica (DMAC) Q1 2025: R&D Spend Jumps 54% as Preeclampsia and Stroke Trials Accelerate
Diametica’s first quarter saw a substantial ramp in R&D investment, with clinical momentum building in both preeclampsia and stroke trials. The company is approaching a pivotal dose selection milestone for its preeclampsia program and reported improved enrollment dynamics in its global stroke study. Cash runway extends into Q3 2026, but execution hinges on timely trial progress and clear upcoming readouts.
Summary
- Clinical Milestones Nearing: Key preeclampsia Phase II dose selection and top-line data expected by July.
- Stroke Trial Enrollment Gains: Remedy 2 enrollment momentum improves, with high-volume sites outperforming expectations.
- Cash Burn and Runway: Elevated R&D spend reduces cash reserves, but funding is secured into Q3 2026.
Performance Analysis
Diametica’s Q1 results reflect a company in the midst of aggressive clinical execution. Research and development expenses rose to $5.7 million, up 54% year-over-year, driven by the continued expansion of the Remedy 2 stroke trial and increased manufacturing and clinical team costs. General and administrative expenses ticked up to $2.5 million, largely due to non-cash share-based compensation linked to a board member’s retirement. Net cash used in operating activities reached $7.1 million, with cash and investments at quarter-end totaling $37.3 million. This represents a decline from $44.1 million at year-end, directly attributable to the stepped-up clinical activity.
The business model remains pre-commercial, with Diametica focused on advancing two core assets: DM-199 for preeclampsia and acute ischemic stroke. The company’s cash runway, now guiding into Q3 2026, is a function of ongoing trial costs and moderate increases in R&D projected for future quarters. Interest income fell as average balances declined, and management expects G&A to remain steady, absent further non-recurring items.
- R&D Outpaces Revenue: Clinical trial expansion and manufacturing scale-up drive most of the spend, reflecting a pipeline-centric operating model.
- Cash Position Monitored: Quarter-end cash supports operations into the second half of next year, but continued high burn rates will require milestone-driven discipline.
- Operating Leverage to Come: No commercial revenue yet, so future value creation is tied to clinical progress and de-risking events.
In sum, the quarter underscores Diametica’s transition from planning to clinical execution, with upcoming trial data as the catalyst for future valuation inflection.
Executive Commentary
"We believe Part 1A of our Phase 2 investigator-sponsored preeclampsia trial is very close to identifying a target dose to move forward within in Part 1B. Dose selection will be guided primarily by a few key data points, which we expect to be sharing in our upcoming preliminary top-line results from the Part 1A proof-of-concept portion of the trial."
Rick Pauls, President and Chief Executive Officer
"We anticipate that our current cash and investments provides us a runway into Q3 of 2026. Our research and development expenses increased to $5.7 million for the three months ended March 31, 2025, up from $3.7 million for the three months ended March 31, 2024. The increase was due primarily to cost increases resulting from the continuation of our Remedy 2 clinical trial, including our global expansion, increased manufacturing development activity, and the expansion of our clinical team during 2024."
Scott Kellan, Chief Financial Officer
Strategic Positioning
1. Preeclampsia Program: Approaching Proof-of-Concept Readout
Diametica’s lead preeclampsia asset, DM-199, is nearing a critical Phase II milestone, with Part 1A top-line data expected by early July. The trial’s dose selection will be informed by safety, blood pressure reduction, and uterine artery pulsatility index changes—a surrogate for disease modification. The company is positioning DM-199 as the only novel agent in clinical development for preeclampsia, aiming to fill a significant unmet need in maternal health. Near-term focus remains on executing Part 1B, with future plans to expand the trial globally, including into the U.S.
2. Remedy 2 Stroke Trial: Enrollment Momentum and Site Optimization
Remedy 2, the company’s global acute ischemic stroke trial, is now between the 20th and 25th percentile of interim enrollment, with high-volume sites exceeding expectations and underperforming centers being shut down. Recent operational changes—including engaging an experienced stroke neurologist—have driven improved site engagement and study logistics, supporting the interim analysis timeline for the first half of 2026. The focus is on maintaining and amplifying this enrollment curve to hit critical data milestones.
3. Capital Allocation and Operational Discipline
Diametica’s capital allocation is tightly linked to clinical milestones, with the majority of spend directed at trial execution and manufacturing scale-up. Management is signaling discipline by actively managing site performance and containing G&A growth. The cash runway to Q3 2026 is contingent on current burn rates, which are expected to rise moderately as both programs advance but are being closely watched for efficiency.
Key Considerations
This quarter marks a transition from planning to clinical proof for Diametica, with execution risk now front and center. The next six months will deliver pivotal data and operational updates that will shape the company’s trajectory.
Key Considerations:
- Preeclampsia Data as Catalyst: Dose selection and top-line readout for DM-199 will validate both the asset and the broader platform’s clinical relevance.
- Stroke Enrollment Curve: High-volume site performance and international expansion are critical to maintaining Remedy 2 momentum and meeting interim analysis timelines.
- Cash Management: Continued high R&D outlays require discipline and may pressure the runway if milestones slip or costs rise unexpectedly.
- Regulatory and Geographic Expansion: Plans to globalize both programs, especially U.S. expansion, will require additional resources and regulatory navigation.
Risks
Diametica faces execution risk in both its clinical programs, with delays in data readouts or enrollment potentially impacting valuation and cash runway. The preeclampsia trial’s reliance on external laboratory timing introduces uncertainty, while the stroke trial’s global complexity requires sustained operational focus. Regulatory expansion and eventual commercial planning remain future challenges, and any negative clinical data could materially affect prospects.
Forward Outlook
For Q2 and Q3 2025, Diametica guided to:
- Release preliminary top-line results for preeclampsia Part 1A between late June and early July
- Advance to Part 1B of the preeclampsia trial in Q3
- Continue Remedy 2 enrollment, targeting 50th percentile update later in 2025
For full-year 2025, management maintained guidance of:
- Cash runway into Q3 2026
- Moderate increases in R&D spend as both programs expand
Management highlighted that timely external lab results and sustained enrollment momentum are key to hitting upcoming milestones and that operational focus will remain on high-value sites and global expansion.
- Preeclampsia proof-of-concept data will drive near-term investor focus
- Remedy 2’s interim analysis remains on track for first half of 2026
Takeaways
Diametica’s investment case now pivots on clinical execution, with two near-term catalysts and a clear focus on operational discipline.
- Trial Milestones Will Drive Value: The next twelve months will see pivotal readouts in preeclampsia and stroke, with dose selection and interim analysis as key inflection points.
- Cash Burn Warrants Monitoring: Elevated R&D spend is necessary for value creation but compresses the timeline before additional capital may be needed, especially if delays arise.
- Watch for U.S. Expansion and Regulatory Updates: Future announcements on geographic trial expansion and regulatory strategy could signal additional upside or complexity.
Conclusion
Diametica’s Q1 2025 results reflect a company in full clinical execution mode, with a clear focus on delivering pivotal trial milestones in preeclampsia and stroke. The next several quarters will be defined by data readouts and operational progress, with cash management and enrollment momentum as critical watchpoints for investors.
Industry Read-Through
Diametica’s focus on preeclampsia and acute ischemic stroke underscores the growing investor interest in under-addressed segments of maternal and neurovascular health. The company’s operational discipline and site optimization strategies are increasingly standard in the biotech sector, as capital efficiency becomes paramount. The lack of FDA-approved therapies for preeclampsia highlights a potential first-mover advantage for Diametica if clinical efficacy is demonstrated, setting a precedent for others in the maternal health space. Meanwhile, the global expansion of stroke trials reflects the need for diverse patient populations and operational agility in large-scale clinical development.